A drug mimics the fat-loss benefits of methionine restriction without destroying bone

Sulfur amino acid restriction works. Reduce methionine and eliminate cysteine from the diet, and obese mice lose fat reliably. The metabolic benefits are well documented across multiple studies. There is just one problem: the diet also destroys bone.

Mice on sulfur amino acid restriction (SAAR) show reduced trabecular and cortical bone mineral density, increased marrow fat, fewer bone-building osteoblasts, and weaker mechanical strength. For a potential anti-obesity strategy, that is a deal-breaker. You cannot solve one health problem by creating another.

A study published in Aging-US offers a way out. Researchers at the Orentreich Foundation for the Advancement of Science have shown that the compound D,L-buthionine-(S,R)-sulfoximine (BSO), which lowers the antioxidant molecule glutathione (GSH), reproduces the fat-loss benefits of SAAR without the bone damage. In obese mice, BSO made them lean. Their bones stayed intact.

Separating fat loss from bone loss

The study, led by Naidu B. Ommi with corresponding author Sailendra N. Nichenametla, used diet-induced obese male C57BL6/NTac mice fed high-fat diets. Four groups were compared: a control diet with normal methionine, a SAAR diet (low methionine, no cysteine), SAAR plus the cysteine precursor N-acetylcysteine (NAC), and a control diet supplemented with BSO in drinking water.

Using body-composition analysis, micro-CT scanning, bone histomorphometry, and biomechanical testing, the team confirmed what previous studies had shown: SAAR reduces body fat but also lowers bone mineral density, increases the amount of fat stored in bone marrow, reduces osteoblast numbers, and weakens bone biomechanical strength.

Here is where it gets interesting. When NAC was added to the SAAR diet, the bone defects reversed. NAC supplies cysteine, which the body uses to make glutathione. This result implicated cysteine and glutathione restriction - not methionine restriction per se - as the driver of bone loss under SAAR.

BSO takes the opposite approach. Instead of restricting cysteine intake, it inhibits an enzyme needed to synthesize glutathione, lowering GSH levels through a different mechanism. The result: BSO-treated mice showed the same lean, anti-obesity phenotype as SAAR mice. But their bones were fine. No loss of mineral density, no increase in marrow fat, no weakening of mechanical strength.

Same metabolic benefit, different biological pathway

The dissociation is the study's key finding. SAAR lowers glutathione by depriving the body of the raw materials to make it, which also eliminates cysteine from the system and triggers a cascade of bone-related damage. BSO lowers glutathione by blocking its synthesis, but cysteine itself remains available in the diet. The bones are spared because the cysteine-dependent processes that maintain bone health continue to function normally.

This suggests that the anti-obesity effects of sulfur amino acid restriction are driven specifically by reduced glutathione levels, while the bone damage is driven by cysteine depletion. BSO separates these two effects, achieving the desired metabolic outcome without the unwanted skeletal consequence.

Far from a human therapy

The researchers were careful not to oversell the finding. BSO is a research tool compound, not a drug candidate. The study was conducted in male mice on high-fat diets - a specific model that may not generalize to other sexes, ages, or dietary conditions. Long-term safety data for BSO are lacking, and the compound's effects on other tissues and organ systems at the doses used have not been fully characterized.

The authors call for mechanistic studies to define how glutathione lowering drives fat loss while sparing bone, investigations of age-at-onset and sex-specific effects, tissue-specific analyses, and long-term safety studies before any clinical development is considered.

What BSO provides at this stage is not a treatment. It is a pharmacological tool that cleanly separates two biological effects that were previously thought to be inseparable. That distinction is valuable for understanding the biology of sulfur amino acid metabolism, and it suggests that anti-obesity strategies targeting the glutathione axis might be possible without the skeletal damage that has made dietary sulfur amino acid restriction impractical.

Whether that possibility leads to an actual therapy is a question for future preclinical work. But the finding that the good effects and bad effects of SAAR can be pulled apart is, at minimum, an important conceptual advance for the field.